---
title: Health-Related Quality of Life in Multiple Myeloma Patients Treated with High-
  or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results
  from the LenaMain Trial (NCT00891384)
date: '2023-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37958331/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231114170859&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: High baseline scores were maintained throughout the trial
  without significant differences between the Len dosages, which supports continuous
  treatment with a dose tailored to patients'' ...'
disable_comments: true
---
CONCLUSION: High baseline scores were maintained throughout the trial without significant differences between the Len dosages, which supports continuous treatment with a dose tailored to patients' ...